Journal ArticleDOI
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
David Cella,David S. Tulsky,G Gray,Bernie Sarafian,E Linn,Amy E. Bonomi,M Silberman,Suzanne B. Yellen,Patsy Winicour,J Brannon +9 more
Reads0
Chats0
TLDR
The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change.Abstract:
PURPOSEWe developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale.METHODS AND RESULTSThe five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The ...read more
Citations
More filters
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.
Journal ArticleDOI
The PedsQL: measurement model for the pediatric quality of life inventory.
TL;DR: The results support the PedsQL as a reliable and valid measure of HRQOL and makes it flexible enough to be used in a variety of research and clinical applications for pediatric chronic health conditions.
Journal ArticleDOI
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Thomas J. Lynch,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +15 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +14 more
TL;DR: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy as mentioned in this paper.
Journal ArticleDOI
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson,Pieter Sonneveld,Michael W. Schuster,D. Irwin,Edward A. Stadtmauer,Thierry Facon,Jean-Luc Harousseau,Dina Ben-Yehuda,Sagar Lonial,Hartmut Goldschmidt,Donna E. Reece,Jesús F. San-Miguel,Joan Bladé,Mario Boccadoro,Jamie Cavenagh,William S. Dalton,Anthony Boral,Dixie Lee Esseltine,Jane B. Porter,David P. Schenkein,Kenneth C. Anderson +20 more
TL;DR: Bortezomib is superior to high-dose dexamethasone for the treatment of patients with multiple myeloma who have had a relapse after one to three previous therapies.
References
More filters
Book
Using multivariate statistics
TL;DR: In this Section: 1. Multivariate Statistics: Why? and 2. A Guide to Statistical Techniques: Using the Book Research Questions and Associated Techniques.
Journal ArticleDOI
A personality scale of manifest anxiety.
TL;DR: A description of the construction of the test and the normative data that have been accumulated in connection with it are presented as of possible interest to other researchers.
Journal ArticleDOI
Short, homogeneous versions of the Marlow‐Crowne Social Desirability Scale
Journal ArticleDOI
Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.
Walter O. Spitzer,Walter O. Spitzer,Annette J. Dobson,Annette J. Dobson,Jane Hall,Jane Hall,Esther Chesterman,Esther Chesterman,John Levi,John Levi,Richard Shepherd,Richard Shepherd,Renaldo N. Battista,Renaldo N. Battista,Barry R. Catchlove,Barry R. Catchlove +15 more
TL;DR: The aim has been to provide a new measure that can help physicians assess the relative benefits and risks of various treatments for serious illness and of supportive programs such as palliative care or hospice service.
Journal ArticleDOI
Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
TL;DR: The Functional Living Index-Cancer is proposed as an adjunct to clinical trials assessment and may provide additional patient functional information on which to analyse the outcome of clinical trials or offer specific advice to individual patients.
Related Papers (5)
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
John E. Ware,Cathy D. Sherbourne +1 more